Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 740-748

  Rodriguez Galan, Maria Cecilia ^a   Reynolds, Della ^a   Correa, Silvia G ^b   Iribarren, Pablo ^a   Watanabe, Morihiro ^a   Young, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 18; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOASSAY; IMMUNOCYTOTOXICITY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; DRUG COMBINATION; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METASTASIS; MORTALITY; MOUSE MUTANT; PHYSIOLOGY; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DRUG THERAPY, COMBINATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-18; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68949092271     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804166     Document Type: Article

References (52)

1. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70: 83-243. (Pubitemid 128678837)
2. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
3. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877-3882. (Pubitemid 26129617)
4. Mazzolini, G., J. Prieto, and I. Melero. 2003. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 9: 1981-1991.
5. Rakhmilevich, A. L., J. G. Timmins, K. Janssen, E. L. Pohlmann, M. J. Sheehy, and N. S. Yang. 1999. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J. Immunother. 22: 135-144.
6. Rook, A. H., M. H. Zaki, M. Wysocka, G. S. Wood, M. Duvic, L. C. Showe, F. Foss, M. Shapiro, T. M. Kuzel, E. A. Olsen, et al. 2001. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941: 177-184.
7. Shurin, M. R., C. Esche, J. M. Peron, and M. T. Lotze. 1997. Antitumor activities of IL-12 and mechanisms of action. Chem. Immunol. 68: 153-174.
8. Ansell, S. M., T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, and C. Erlichman. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99: 67-74.
9. Pelloso, D., K. Cyran, L. Timmons, B. T. Williams, and M. J. Robertson. 2004. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation. Clin. Cancer Res. 10: 1935-1942.
10. Hamid, O., J. C. Solomon, R. Scotland, M. Garcia, S. Sian, W. Ye, S. L. Groshen, and J. S. Weber. 2007. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin. Cancer Res. 13: 215-222.
11. Lenzi, R., R. Edwards, C. June, M. V. Seiden, M. E. Garcia, M. Rosenblum, and R. S. Freedman. 2007. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J. Transl. Med. 5: 66.
12. Yarchoan, R., J. M. Pluda, K. M. Wyvill, K. Aleman, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. F. Little. 2007. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity. Crit. Rev. Immunol. 27: 401-414.
13. Portielje, J. E., W. H. Kruit, M. Schuler, J. Beck, C. H. Lamers, G. Stoter, C. Huber, M. de Boer-Dennert, A. Rakhit, R. L. Bolhuis, and W. E. Aulitzky. 1999. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5: 3983-3989.
14. Labbe, A., M. Nelles, J. Walia, L. Jia, C. Furlonger, T. Nonaka, J. A. Medin, and C. J. Paige. 2008. IL-12 Immunotherapy of murine leukemia: comparison of systemic versus gene modified cell therapy. J. Cell Mol. Med. In press.
15. Lui, V. W., Y. He, L. Falo, and L. Huang. 2002. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum. Gene Ther. 13: 177-185.
16. Robertson, M. J., D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson, Jr., L. Wood, and K. Cornetta. 2002. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin. Cancer Res. 8: 3383-3393.
17. Younes, A., B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al. 2004. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin. Cancer Res. 10: 5432-5438.
18. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417.
19. Robertson, M. J., C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz. 1999. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5: 9-16.
20. Egilmez, N. K., M. O. Kilinc, T. Gu, and T. F. Conway. 2007. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr. Metab. Immune Disord. Drug Targets 7: 266-270.
21. + melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7: 895s-901s.
22. Watanabe, M., K. L. McCormick, K. Volker, J. R. Ortaldo, J. M. Wigginton, M. J. Brunda, R. H. Wiltrout, and W. E. Fogler. 1997. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol. 150: 1869-1880.
23. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. F. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101: 1441-1452.
24. Lui, V. W., L. D. Falo, Jr., and L. Huang. 2001. Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expression in vivo. J. Gene Med. 3: 384-393.
25. Brehm, M. A., K. A. Daniels, J. R. Ortaldo, and R. M. Welsh. 2005. Rapid conversion of effector mechanisms from NK to T cells during virus-induced lysis of allogeneic implants in vivo. J. Immunol. 174: 6663-6671.
26. Cassataro, J., C. A. Velikovsky, S. de la Barrera, S. M. Estein, L. Bruno, R. Bowden, K. A. Pasquevich, C. A. Fossati, and G. H. Giambartolomei. 2005. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect. Immun. 73: 6537-6546.
27. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266. (Pubitemid 29359019)
28. Ortaldo, J. R., R. Winkler-Pickett, J. Willette-Brown, R. L. Wange, S. K. Anderson, G. J. Palumbo, L. H. Mason, and D. W. McVicar. 1999. Structure/function relationship of activating Ly-49D and inhibitory Ly-49G2 NK receptors. J. Immunol. 163: 5269-5277.
29. Carson, W. E., J. E. Dierksheide, S. Jabbour, M. Anghelina, P. Bouchard, G. Ku, H. Yu, H. Baumann, M. H. Shah, M. A. Cooper, J. Durbin, and M. A. Caligiuri. 2000. Coadministration of interleukin-18 and interleukin-12 induces a fatal in- flammatory response in mice: critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction. Blood 96: 1465-1473.
30. Nakamura, S., T. Otani, Y. Ijiri, R. Motoda, M. Kurimoto, and K. Orita. 2000. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 164: 3330-3336.
31. Mazzolini, G., I. Narvaiza, A. Perez-Diez, M. Rodriguez-Calvillo, C. Qian, B. Sangro, J. Ruiz, J. Prieto, and I. Melero. 2001. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther. 8: 259-267.
32. Fehniger, T. A., M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri. 1999. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162: 4511-4520.
33. Hoshino, T., R. H. Wiltrout, and H. A. Young. 1999. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162: 5070-5077.
34. Rodriguez-Galan, M. C., J. H. Bream, A. Farr, and H. A. Young. 2005. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. J. Immunol. 174: 2796-2804.
35. Meyaard, L., E. Hovenkamp, S. A. Otto, and F. Miedema. 1996. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J. Immunol. 156: 2776-2782.
36. O'Garra, A., and P. Vieira. 2007. Th1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7: 425-428.
37. Ito, H., N. Koide, F. Hassan, S. Islam, G. Tumurkhuu, I. Mori, T. Yoshida, S. Kakumu, H. Moriwaki, and T. Yokochi. 2006. Lethal endotoxic shock using α-galactosylceramide sensitization as a new experimental model of septic shock. Lab. Invest. 86: 254-261.
38. Tsuji, H., N. Mukaida, A. Harada, S. Kaneko, E. Matsushita, Y. Nakanuma, H. Tsutsui, H. Okamura, K. Nakanishi, Y. Tagawa, et al. 1999. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-γ-deficient mice by a concomitant reduction of TNF-α, IL-12, and IL-18 production. J. Immunol. 162: 1049-1055. (Pubitemid 29035433)
39. Gollob, J. A., J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins. 2000. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6: 1678-1692.
40. Portielje, J. E., J. W. Gratama, H. H. van Ojik, G. Stoter, and W. H. Kruit. 2003. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52: 133-144.
41. Hashimoto, W., T. Osaki, H. Okamura, P. D. Robbins, M. Kurimoto, S. Nagata, M. T. Lotze, and H. Tahara. 1999. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol. 163: 583-589. (Pubitemid 29328059)
42. Osaki, T., J. M. Peron, Q. Cai, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160: 1742-1749. (Pubitemid 28106460)
43. Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19: 423-474.
44. Kinoshita, M., N. Kuranaga, A. Matsumoto, S. Ono, N. Shinomiya, H. Hiraide, and S. Seki. 2006. Multiple interleukin-18 injections promote both mouse Th1 and Th2 responses after sublethal Escherichia coli infection. Clin. Exp. Immunol. 143: 41-49.
45. Car, B. D., V. M. Eng, B. Schnyder, M. LeHir, A. N. Shakhov, G. Woerly, S. Huang, M. Aguet, T. D. Anderson, and B. Ryffel. 1995. Role of interferon-γ in interleukin 12-induced pathology in mice. Am. J. Pathol. 147: 1693-1707.
46. Carson, W. E., H. Yu, J. Dierksheide, K. Pfeffer, P. Bouchard, R. Clark, J. Durbin, A. S. Baldwin, J. Peschon, P. R. Johnson, et al. 1999. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J. Immunol. 162: 4943-4951.
47. Zeerleder, S., C. E. Hack, C. Caliezi, G. van Mierlo, A. Eerenberg-Belmer, A. Wolbink, and W. A. Wuillenmin. 2005. Activated cytotoxic T cells and NK cells in severe sepsis and septic shock and their role in multiple organ dysfunction. Clin. Immunol. 116: 158-165.
48. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495-521.
49. Portielje, J. E., C. H. Lamers, W. H. Kruit, A. Sparreboom, R. L. Bolhuis, G. Stoter, C. Huber, and J. W. Gratama. 2003. Repeated administration of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFNγ, tumor necrosis factor-α, IL-6 and IL-8 responses. Clin. Cancer Res. 9: 76-83.
50. Chandra, A., P. Enkhbaatar, Y. Nakano, L. D. Traber, and D. L. Traber. 2006. Sepsis: emerging role of nitric oxide and selectins. Clinics 61: 71-76.
51. - Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J. Exp. Med. 204: 273-283.
52. Gerosa, F., C. Paganin, D. Peritt, F. Paiola, M. T. Scupoli, M. ste-Amezaga, I. Frank, and G. Trinchieri. 1996. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J. Exp. Med. 183: 2559-2569.